Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells

被引:29
|
作者
Wang, Quan [1 ,2 ]
He, Wei-Yang [1 ]
Zeng, Yi-Zhou [1 ,2 ]
Hossain, Arman [1 ,2 ]
Gou, Xin [1 ]
机构
[1] Chongqing Med Univ, Dept Urol, Affiliated Hosp 1, Chongqing 400016, Peoples R China
[2] Chongqing Med Univ, Cent Lab, Affiliated Hosp 1, Chongqing 400016, Peoples R China
关键词
Castration-resistant prostate cancer; Docetaxel resistance; Autophagy; Tea polyphenol; STARVATION-INDUCED AUTOPHAGY; SIGNAL-REGULATED KINASE; TEA POLYPHENOLS; GREEN TEA; ACTIVATION; SENSITIVITY; APOPTOSIS; PATHWAY; PREVENTION; EXPRESSION;
D O I
10.1007/s11255-018-1801-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
This study investigates the docetaxel-resistant mechanism and explores the effect of tea polyphenols (TP) on autophagy and its related mechanism in human castration-resistant prostate cancer (CRPC) cell lines PC3 and DU145. Immunofluorescence assay and annexin V-FITC/PI double staining flow cytometry were used to analyze the apoptosis and autophagy of PC3 and DU145 cells. The expression of autophagy-related proteins was detected by western bolt. Docetaxel could induce autophagy and apoptosis, together with the expression increase in p-JNK, p-Bcl-2 and Beclin1. The level of autophagy was remarkably decreased, but apoptosis was increased after combining with TP. In addition, the expression of p-mTOR was increased after combining with TP. Docetaxel induces protective autophagy in CRPC cells by JNK pathway activation and then Bcl-2 phosphorylation and Beclin1 dissociation. TP activates mTOR pathway, which ultimately inhibits docetaxel-induced autophagy and improves therapeutic efficacy of docetaxel in CRPC cells.
引用
收藏
页码:675 / 686
页数:12
相关论文
共 50 条
  • [31] FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy
    Lin, Jian-zhong
    Wang, Wei-wan
    Hu, Ting-ting
    Zhu, Gang-yi
    Li, Li-nan
    Zhang, Cheng-yang
    Xu, Zheng
    Yu, Hong-bo
    Wu, Hong-fei
    Zhu, Jia-geng
    CANCER LETTERS, 2020, 469 : 481 - 489
  • [32] NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer
    Chen, Zhixiong
    Jiang, Qilong
    Zhu, Pingyu
    Chen, Yanlin
    Xie, Xuemei
    Du, Zhongbo
    Jiang, Li
    Tang, Wei
    PROSTATE, 2019, 79 (01): : 44 - 53
  • [33] CIRCULATING MICRORNAS ASSOCIATED WITH DOCETAXEL-RESISTANT CASTRATION-RESISTANT PROSTATE CANCER
    Mahon, K. L.
    Chiam, K.
    Lee, B. Y.
    Nguyen, Q.
    Boyer, M. J.
    Stockler, M.
    Pavlakis, N.
    Marx, G.
    Mallesara, G.
    Gurney, H.
    Clark, S.
    Swarbrick, A.
    Daly, R.
    Horvath, Lisa
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 26 - 27
  • [34] Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate
    Akiyuki Yamamoto
    Masashi Kato
    Hirotaka Matsui
    Ryo Ishida
    Tohru Kimura
    Yasuhito Funahashi
    Naoto Sassa
    Yoshihisa Matsukawa
    Osamu Kamihira
    Ryohei Hattori
    Momokazu Gotoh
    Toyonori Tsuzuki
    International Journal of Clinical Oncology, 2018, 23 : 584 - 590
  • [35] Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate
    Yamamoto, Akiyuki
    Kato, Masashi
    Matsui, Hirotaka
    Ishida, Ryo
    Kimura, Tohru
    Funahashi, Yasuhito
    Sassa, Naoto
    Matsukawa, Yoshihisa
    Kamihira, Osamu
    Hattori, Ryohei
    Gotoh, Momokazu
    Tsuzuki, Toyonori
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (03) : 584 - 590
  • [36] TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer
    Reig, Oscar
    Marin-Aguilera, Mercedes
    Carrera, Gemma
    Jimenez, Natalia
    Pare, Laia
    Garcia-Recio, Susana
    Gaba, Lydia
    Veronica Pereira, Maria
    Fernandez, Pedro
    Prat, Aleix
    Mellado, Begona
    EUROPEAN UROLOGY, 2016, 70 (05) : 709 - 713
  • [37] Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
    Chandrasekar, Thenappan
    Yang, Joy C.
    Gao, Allen C.
    Evans, Christopher P.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2015, 4 (03) : 365 - 380
  • [38] Docetaxel-based combination therapy for castration-resistant prostate cancer
    Galsky, M. D.
    Vogelzang, N. J.
    ANNALS OF ONCOLOGY, 2010, 21 (11) : 2135 - 2144
  • [39] What is the appropriate use of palliative docetaxel in castration-resistant prostate cancer?
    Steineck, Gunnar
    Glimelius, Bengt
    ACTA ONCOLOGICA, 2013, 52 (08) : 1589 - 1592
  • [40] Drug resistance in metastatic castration-resistant prostate cancer
    Bostjan Seruga
    Alberto Ocana
    Ian F. Tannock
    Nature Reviews Clinical Oncology, 2011, 8 : 12 - 23